The Role of Lipids in Immune Cell Function in SLE Patients
2020年4月22日 更新者:University College, London
Understanding the Role Played by Serum and Membrane Lipids in Immune Cell Function in Patients With Systemic Lupus Erythematosus (SLE) and Healthy Donors
The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors.
We know that the amount of fat on the surface of immune cells is an important factor controlling their behaviour.
Immune cells from SLE patients are defective and this is associated with changes in the levels of fat on these cells.
This project will investigate the level of fat in the blood and on immune cells from patients with SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.
研究概览
地位
未知
条件
详细说明
Accelerated atherosclerosis is a serious complication of autoimmunity including patients with both adult and juvenile onset systemic lupus erythematosus (SLE).
This suggests that defects in fat levels could contribute to disease pathogenesis.
The immune system in patients with SLE does not work normally.
In adult patients with SLE we know that many of the immune cells involved in protecting the body from infections or cancer are over-active and actually cause disease.
In young people the immune system is still developing and very little is known about what goes wrong in patients that develop juvenile-onset SLE, whether this is the same as adult disease and whether the same treatments are relevant for this group of patients.
This project aims to find out whether immune cells from SLE patients with adult-onset disease have the same defects as adult patients with juvenile-onset SLE.
We know that an important factor that controls immune cell behaviour is the amount of fat that they have on their surface.
We also know that a change in fat on immune cells from adult patients with SLE makes them defective.
This project will investigate the level of fat in the blood and in immune cells from adult patients with juvenile-onset SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.
We will investigate how drugs that control fat levels can help to normalize the behaviour of immune cells from SLE patients.
研究类型
观察性的
注册 (预期的)
300
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
London、英国、NW1 2BU
- 招聘中
- University College London Hospitals NHS Foundation Trust
-
接触:
- George Robinson, Dr
- 电话号码:02031082167
- 邮箱:george.robinson.15@ucl.ac.uk
-
接触:
- Amanda Ledlie
- 电话号码:02031082167
- 邮箱:a.ledlie@ucl.ac.uk
-
首席研究员:
- David Isenberg, Prof
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 80年 (成人、年长者)
接受健康志愿者
不适用
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Patients will be approached by the consultant rheumatologist when the patient is attending their normal outpatient clinic appointment.
Healthy donors will be approached in a similar way using information flyers, invitation letters and participant information sheets by a member of the research team.
Healthy volunteers from UCL staff will be made aware of the study and also asked to participate.
描述
Inclusion Criteria:
- Diagnosis of SLE according to American College of Rheumatology revised criteria
- Having given written informed consent prior to undertaking any study-related procedures.
- Male and female patients between the ages of 18 and 80 years.
Patients who have met all the above inclusion criteria listed and healthy donors will be screened for the following exclusion criteria:
Exclusion Criteria:
- Under any administrative or legal supervision.
- Conditions/situations such as:
- A concomitant autoimmune disease
- Impossibility to meet specific protocol requirements (e.g. blood sampling).
- Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures.
- Pregnant or breast-feeding women, currently or in the last three months prior to inclusion.
- Patients who have been vaccinated in the last three months prior to inclusion.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Juvenile onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
|
其他名称:
|
|
Adult onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
|
其他名称:
|
|
Matching healthy volunteers
Healthy volunteers, matched by age and gender, will be used as a control group
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Collection of blood samples
大体时间:4 hours from point of sample collection
|
Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
|
4 hours from point of sample collection
|
|
Completion of FFQ's and/or diet recall questionnaires
大体时间:Same day as recruited to study.
|
FFQ's and/or diet recall questionnaires to assess dietary intake
|
Same day as recruited to study.
|
|
Cardiovascular Ultrasound scans (USS)
大体时间:Within 2 months from recruitment.
|
USS of Intima Media Thickness (IMT), Flow Mediated Dilatation (FMD), Pulse Wave Velocity (PWV) and Laser Doppler Flowmetry measurement.
As part of the procedure, sub lingual administration of GTN spray will be administered to measure FMD.
|
Within 2 months from recruitment.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:David Isenberg, Prof、UCL & University College London Hospitals NHS Foundation Trust
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年2月15日
初级完成 (预期的)
2020年8月31日
研究完成 (预期的)
2020年8月31日
研究注册日期
首次提交
2020年4月22日
首先提交符合 QC 标准的
2020年4月22日
首次发布 (实际的)
2020年4月24日
研究记录更新
最后更新发布 (实际的)
2020年4月24日
上次提交的符合 QC 标准的更新
2020年4月22日
最后验证
2020年4月1日
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
IPD 计划说明
All participants are required to indicate in written consent if they agree to the use of any left over samples and associated data for future research use.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.